Study of Adjunctive Ganaxolone Treatment in Children and Young Adults With CDKL5 Deficiency Disorder
Completed · Phase 3 · NCT03572933
Conditions: CDKL5 Deficiency Disorder
At a glance
- Research payments reported, 2025
- $1,690
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 101
About the trial
- Sponsor
- Marinus Pharmaceuticals
- Tested
- ganaxolone (drug), Placebo (drug)
- Dates
- Started 2018-06-30; completion 2021-05-28
- Results posted
- Yes
A clinical study to evaluate the efficacy, safety, and tolerability of adjunctive ganaxolone therapy compared to placebo for the treatment of seizures in children and young adults with genetically confirmed CDKL5 gene mutation.
From ClinicalTrials.gov, last updated 2023-04-14. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Immedica Pharma US, Inc. reported $1,690 in research payments for this study in 2025 (2 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.